A citation-based method for searching scientific literature

L Meyer, V Durlach, F X Maquart, P Gillery, H Grulet, M Leutenegger. Rev Med Interne 1992
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Can positron emission mammography help to identify clinically significant breast cancer in women with suspicious calcifications on mammography?
Almir G V Bitencourt, Eduardo N P Lima, Bruna R C Macedo, Jorge L F A Conrado, Elvira F Marques, Rubens Chojniak. Eur Radiol 2017
7
50

Ductal carcinoma in situ: correlation between FDG-PET/CT and histopathology.
Asako Azuma, Mitsuhiro Tozaki, Kensuke Ito, Eisuke Fukuma, Tomoko Tanaka, Toshihiro O'uchi. Radiat Med 2008
11
50

[Photochemical reduction of chlorophyll analogs by tryptophan].
A V Umrikhina, A A Krasnovskiĭ. Biokhimiia 1969
1
100

In situ breast carcinomas: a population-based study on frequency, growth pattern, and clinical aspects.
M Blichert-Toft, H P Graversen, J Andersen, U Dyreborg, A Green. World J Surg 1988
20
50



Effect of retained components of excised tumor upon coexisting tumor.
K Arai, H W Wallace, T Asakura, P Nemir. J Surg Res 1989
2
50

Genetic predisposition to ductal carcinoma in situ of the breast.
Christos Petridis, Mark N Brook, Vandna Shah, Kelly Kohut, Patricia Gorman, Michele Caneppele, Dina Levi, Efterpi Papouli, Nick Orr, Angela Cox,[...]. Breast Cancer Res 2016
29
50

Breast cancer precursors revisited: molecular features and progression pathways.
Maria A Lopez-Garcia, Felipe C Geyer, Magali Lacroix-Triki, Caterina Marchió, Jorge S Reis-Filho. Histopathology 2010
187
50

Ten-year follow-up of breast carcinoma in situ in Connecticut.
B A Ward, C F McKhann, T S Ravikumar. Arch Surg 1992
29
50


Early lymphocyte activation molecule defined by the monoclonal antibody MLR-3: biochemical and functional studies.
D Delia, C Traversari, D Ballinari, G Cattoretti, E Fontanella, N Polli, G Della Porta. Immunology 1988
14
50

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
E Senkus, S Kyriakides, S Ohno, F Penault-Llorca, P Poortmans, E Rutgers, S Zackrisson, F Cardoso. Ann Oncol 2015
887
50

Comparison of GLUT-1, SGLT-1, and SGLT-2 expression in false-negative and true-positive lymph nodes during the 18F-FDG PET/CT mediastinal nodal staging of non-small cell lung cancer.
Naohiro Taira, Eriko Atsumi, Saori Nakachi, Reika Takamatsu, Tomofumi Yohena, Hidenori Kawasaki, Tsutomu Kawabata, Naoki Yoshimi. Lung Cancer 2018
9
50



Molecular evolution of breast cancer.
Peter T Simpson, Jorge S Reis-Filho, Theodora Gale, Sunil R Lakhani. J Pathol 2005
338
50


Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.
N Avril, C A Rosé, M Schelling, J Dose, W Kuhn, S Bense, W Weber, S Ziegler, H Graeff, M Schwaiger. J Clin Oncol 2000
353
50

Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study.
Tomoyuki Fujioka, Kazunori Kubota, Akira Toriihara, Youichi Machida, Kaori Okazawa, Tsuyoshi Nakagawa, Yukihisa Saida, Ukihide Tateishi. World J Radiol 2016
9
50

Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage I-III Breast Cancer: Comparison With Standard PET/CT.
Suzana C Teixeira, José Ferrér Rebolleda, Bas B Koolen, Jelle Wesseling, Raúl Sánchez Jurado, Marcel P M Stokkel, María Del Puig Cózar Santiago, Vincent van der Noort, Emiel J Th Rutgers, Renato A Valdés Olmos. AJR Am J Roentgenol 2016
20
50

First clinical experience with a dedicated PET for hanging breast molecular imaging.
B B Koolen, T S Aukema, A J González Martínez, W V Vogel, L Caballero Ontanaya, M J Vrancken Peeters, C J J Vroonland, E J Rutgers, J M Benlloch Baviera, R A Valdés Olmos. Q J Nucl Med Mol Imaging 2013
14
50

Evaluation of Apparent Diffusion Coefficient to Predict Grade, Microinvasion, and Invasion in Ductal Carcinoma In Situ of the Breast.
Heba Hussein, Caroline Chung, Hadas Moshonov, Naomi Miller, Supriya R Kulkarni, Anabel M Scaranelo. Acad Radiol 2015
11
50


Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
K Han, S Nofech-Mozes, S Narod, W Hanna, D Vesprini, R Saskin, C Taylor, I Kong, L Paszat, E Rakovitch. Clin Oncol (R Coll Radiol) 2012
34
50

Cancer statistics, 2018.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2018
50

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
Lotte E Elshof, Konstantinos Tryfonidis, Leen Slaets, A Elise van Leeuwen-Stok, Victoria P Skinner, Nicolas Dif, Ruud M Pijnappel, Nina Bijker, Emiel J Th Rutgers, Jelle Wesseling. Eur J Cancer 2015
184
50

Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons.
D Rosner, R N Bedwani, J Vana, H W Baker, G P Murphy. Ann Surg 1980
256
50

Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake.
R S Brown, J Y Leung, S J Fisher, K A Frey, S P Ethier, R L Wahl. J Nucl Med 1996
114
50

Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
N Avril, M Menzel, J Dose, M Schelling, W Weber, F Jänicke, W Nathrath, M Schwaiger. J Nucl Med 2001
302
50


Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Karla Kerlikowske, Annette M Molinaro, Mona L Gauthier, Hal K Berman, Fred Waldman, James Bennington, Henry Sanchez, Cynthia Jimenez, Kim Stewart, Karen Chew,[...]. J Natl Cancer Inst 2010
231
50


Over-expression of facilitative glucose transporter genes in human cancer.
T Yamamoto, Y Seino, H Fukumoto, G Koh, H Yano, N Inagaki, Y Yamada, K Inoue, T Manabe, H Imura. Biochem Biophys Res Commun 1990
403
50


Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast.
Anne Vincent-Salomon, Carlo Lucchesi, Nadège Gruel, Virginie Raynal, Gaëlle Pierron, Rémi Goudefroye, Fabien Reyal, François Radvanyi, Rémy Salmon, Jean-Paul Thiery,[...]. Clin Cancer Res 2008
111
50

The usefulness of fluorodeoxyglucose-PET/CT for preoperative evaluation of ductal carcinoma in situ.
Sungchul Kim, Seokjae Lee, Sangwon Kim, Seokmo Lee, Hayong Yum. Ann Surg Treat Res 2018
1
100

Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Stacey K Mardekian, Alessandro Bombonati, Juan P Palazzo. Hum Pathol 2016
30
50

Addressing overtreatment of screen detected DCIS; the LORIS trial.
Adele Francis, Jeremy Thomas, Lesley Fallowfield, Matthew Wallis, John M S Bartlett, Cassandra Brookes, Tracy Roberts, Sarah Pirrie, Claire Gaunt, Jennie Young,[...]. Eur J Cancer 2015
194
50



Expression of glucose transporter-1 in Taiwanese patients with breast carcinoma--a preliminary report.
Shou-Jen Kuo, Yao-Chung Wu, Chun-Ping Chen, Hsin-Shun Tseng, Dar-Ren Chen. Kaohsiung J Med Sci 2006
7
50

Improved visualization of breast tissue on a dedicated breast PET system through ergonomic redesign of the imaging table.
Michael K O'Connor, Thuy D Tran, Tiffinee N Swanson, Lacey R Ellingson, Katie N Hunt, Dana H Whaley. EJNMMI Res 2017
6
50

Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging.
Kathy Schilling, Deepa Narayanan, Judith E Kalinyak, Juliette The, Maria Victoria Velasquez, Simone Kahn, Matthew Saady, Ravinder Mahal, Larraine Chrystal. Eur J Nucl Med Mol Imaging 2011
62
50

The molecular genetics of breast cancer: the contribution of comparative genomic hybridization.
Jorge S Reis-Filho, Peter T Simpson, Theodora Gale, Sunil R Lakhani. Pathol Res Pract 2005
79
50

The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).
E Shelley Hwang, Terry Hyslop, Thomas Lynch, Elizabeth Frank, Donna Pinto, Desiree Basila, Deborah Collyar, Antonia Bennett, Celia Kaplan, Shoshana Rosenberg,[...]. BMJ Open 2019
94
50

Patient Selection for Ductal Carcinoma In Situ Observation Trials: Are the Lesions Truly Low Risk?
Gitanjali V Patel, Eduardo Pascual Van Sant, Bret Taback, Richard Ha. AJR Am J Roentgenol 2018
10
50

Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes.
Ayse Mavi, Muammer Urhan, Jian Q Yu, Hongming Zhuang, Mohamed Houseni, Tevfik F Cermik, Dhurairaj Thiruvenkatasamy, Brian Czerniecki, Mitchell Schnall, Abass Alavi. J Nucl Med 2006
122
50

Ductal carcinoma in situ and ductal carcinoma in situ with microinvasion: correlation of FDG uptake with histological and biological prognostic factors.
Ye Young Seo, Ie Ryung Yoo, Sonya Youngju Park, Jin Kyoung Oh, Sung Hoon Kim, Hyung Sun Sohn. Breast Cancer 2017
3
50

Dedicated breast PET value to evaluate BI-RADS 4 breast lesions.
L Graña-López, M Herranz, I Domínguez-Prado, S Argibay, A Villares, A Ruibal, M Vázquez-Caruncho. Eur J Radiol 2018
3
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.